Canaccord Genuity Raises Tempus AI (TEM) Price Target to $95

Canaccord Genuity has reiterated its Buy rating on Tempus AI, increasing the price target to $95, a 45.50% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:28 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Canaccord Genuity raised its price target on Tempus AI, Inc. ($TEM) to $95 from $80 on October 12, 2026, and rates the stock "Buy".

Since the rating, $TEM is down 4.8% to date (from the $67.99 close on Oct 12, 2026).

TEM Tempus AI, Inc.

$64.72 +3.78% year to date

Daily close · Oct 16, 2026

Key Points

Canaccord Genuity reiterated its Buy rating on Tempus AI, Inc. with a new price target of $95 on October 12, 2026.
Canaccord Genuity's $95 price target implies 45.50% upside from Tempus AI, Inc.'s ($TEM) current $65.29 share price.
The stock recently traded around $65.29, which is 31.3% below Canaccord's updated target.
Tempus AI has a market cap of about $12.8 billion and is set to report earnings on November 2, 2026.

Get $TEM trade alerts by text

We text you when insiders, Congress or big funds trade $TEM. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Tempus AI, Inc. alert may contain errors. Disclosures

Tempus AI, Inc. (NASDAQ: TEM) received a positive update from Canaccord Genuity, which reiterated its Buy rating on October 12, 2026. The firm raised its price target from $80 to $95, reflecting an increased outlook for the healthcare technology company.

Analyst rating track record

Canaccord Genuity vs. the S&P 500

YTD return +1.38% hypothetical

All-time return +1.38% S&P 500 +2.27%

vs. S&P 500 -0.89% behind the index

Hypothetical returns from Canaccord Genuity's disclosed trades, not real profit or advice. How we model this.

Canaccord Genuity's Call on Tempus AI

Canaccord Genuity maintained its Buy rating on Tempus AI, increasing the price target to $95 from a prior target of $80. This indicates a strong belief in the company's future performance, even as the stock currently trades below this target.

Other Institutional Activity in Tempus AI

Several notable funds have positions in Tempus AI. ARK Investment Management, LLC added 415,048 shares, bringing its total to about 10 million shares valued at around $648.7 million. Conversely, BlackRock Inc. reduced its stake by 677,095 shares, ending with about 8.3 million shares worth approximately $536.6 million. Baillie Gifford & Co. also decreased its holdings by 459,284 shares, now holding about 8.2 million shares valued at about $530.1 million.

Tempus AI, Inc. Stock Down 4.4%

As of October 16, 2026, Tempus AI was trading at $65.29, which is 2.5% below its 50-day moving average of $66.96. The stock is 15.1% above its 200-day moving average of $56.72. Currently, it is 31.3% below the average analyst target of $74.94 and 32.2% below its 52-week high of $96.29.

12-month forecast

$TEM price target

Tempus AI, Inc. daily closes and this analyst's $95 target. Not advice.

Recent Earnings

Tempus AI reported trailing twelve-month revenue of approximately $1.43 billion, showing a year-over-year growth rate of 21.6%. However, it recorded a net margin of -17.8% and a negative return on equity of -67.4%. The next earnings report is scheduled for November 2, 2026.

Insider Buying and Selling at Tempus AI, Inc.

Insider activity has included several sales. On September 1, 2026, Director David R. Epstein sold 250 shares at $65.55, totaling about $16,388. Also on that day, Director Jennifer A. Doudna sold 676 shares for approximately $44,312. Additionally, Officer Thomas Edward Schoenherr sold 10,281 shares at $85.00 on September 25, 2026, amounting to about $873,885.

Analysts Set New Price Targets

In addition to Canaccord Genuity's update, other analysts have recently commented on Tempus AI. UBS initiated coverage with a Neutral rating and a price target of $70.00 on September 9, 2026. HC Wainwright & Co. maintained its Buy rating with a target of $66.00, up from $56.00, on September 11, 2026. Goldman Sachs also initiated coverage with a Neutral rating and a price target of $75.00 on September 21, 2026. The consensus among analysts is a Buy rating, with a mean price target of approximately $74.94 based on 18 opinions.

About Tempus AI

Tempus AI, Inc. is a healthcare technology company based in Chicago, Illinois. It provides a platform that integrates clinical data with laboratory diagnostics and analytics. The company's technology aims to enhance healthcare providers' capabilities in delivering precision medicine.

Bottom Line

Investors should keep an eye on Tempus AI's upcoming earnings report on November 2, 2026, and further updates from analysts and institutional investors. Canaccord Genuity's recent price target increase may indicate growing confidence in the company's potential.